Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting

References

• Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist. Urology 1998;51: 861–72
   Google Scholar
• Napalkov P, Maisonneuve P, Boyle P. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 1995;46(Suppl 3A):41–6
   Google Scholar
• Flannery MT. Efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia (BPH): clinical experience in the primary care setting. J Am Geriatr Soc 2001;49:S85 [abstract P229]
   Google Scholar
• McSherry J, Weiss R. Managing benign prostatic hyperplasia in primary care: patient-centered approach. Can Fam Physician 2000;46:383–9
   PubMed Web of Science ®Google Scholar
• Scott-Levin. Physician drug and diagnosis audit, 2000
   Google Scholar
• Fawzy A, Fontenot C, Guthrie R, et al. Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Fam Med 1997;29:321–5
   PubMedGoogle Scholar
• Foglar R, Shibata K, Horie K, et al. Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201–7
   PubMed Web of Science ®Google Scholar
• Narayan P, Djavan B. Prospective, randomized multicenter trial of tamsulosin vs terazosin to evaluate the velocity of the onset of action. J Urol 2002;167:376 [abstract 1497]
   Google Scholar
• Lepor H; for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892–900
   Google Scholar
• Lepor H; for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998;51:901–6
   Google Scholar
• Lee M. Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 2000;34:188–99
   PubMed Web of Science ®Google Scholar
• Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215–28
   Google Scholar
• Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992;149:1393–4
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler Jr FJ, O’Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992;148:1549–57
   Google Scholar
• Barry MJ, Fowler Jr FJ, O’Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995;33(Suppl):AS145–55
   Google Scholar
• Hollander M, Wolfe DA. The one-sample location problem. In: Hollander M, Wolfe DA, editors. Nonparametric statistical methods. New York: John Wiley & Sons; 1973. p. 26–66
   Google Scholar
• Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. Br Med J 1995;310:170
   PubMed Web of Science ®Google Scholar
• Narayan P, Tewari A; members of United States 93–01 Study Group. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998;160: 1701–6
   Google Scholar
• Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170:498–502
   Google Scholar
• Schulman CC, Cortvriend J, Jonas U, et al.; on behalf of the European Tamsulosin Study Group. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol 1999;36: 609–20
   Google Scholar
• Alfuzosin® hydrochloride (uroxatral) prescribing information. New York (NY): Sanofi-Synthelabo; June 2003
   Google Scholar
• de Mey C, Michel MC, McEwen J, et al. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998;33:481–8
   PubMed Web of Science ®Google Scholar
• Lee E, Lee C. Clinical comparison of selective and non-selective a1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606–11
   PubMedGoogle Scholar
• Fawzy A, Braun K, Lewis GP, et al.; for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995;154:105–9
   Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hyper-tensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2000;283:1967–75
   Google Scholar
• Tewari A, Narayan P. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy. Urology 1999;53(Suppl 3A):14–20
   Google Scholar